Notice of Change to Eligibility Information in RFA-AI-21-079, “Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)”
Notice Number:
NOT-AI-22-031

Key Dates

Release Date:

February 4, 2022

Related Announcements

RFA-AI-21-079 - Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice informs potential applicants of a revision to the Eligibility Information in Funding Opportunity Announcement (FOA) RFA-AI-21-079, "Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)".

Effective immediately, the following section of RFA-AI-21-079 has been modified, as indicated below.

Currently Reads:

Section III. Eligibility Information
3. Additional Information on Eligibility

Number of Applications

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

    • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
    • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
    • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).


Modified to Read (changes shown in bold italics):

Section III. Eligibility Information
3. Additional Information on Eligibility

Number of Applications

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

NIAID will not accept applications from institutions that are currently funded under the previous version of this FOA,Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional), RFA-AI-20-007.

The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

    • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
    • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
    • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Gang Dong, MD, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3508
Email: gdong@niaid.nih.gov